BRPI0606923A2 - substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica - Google Patents

substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica

Info

Publication number
BRPI0606923A2
BRPI0606923A2 BRPI0606923-1A BRPI0606923A BRPI0606923A2 BR PI0606923 A2 BRPI0606923 A2 BR PI0606923A2 BR PI0606923 A BRPI0606923 A BR PI0606923A BR PI0606923 A2 BRPI0606923 A2 BR PI0606923A2
Authority
BR
Brazil
Prior art keywords
substance
pharmaceutical formulation
manufacturing
drug
metal
Prior art date
Application number
BRPI0606923-1A
Other languages
English (en)
Inventor
Maurice Sydney Newton
Nigel Peter Rhodes
Alexis John Toft
Original Assignee
Ineos Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ineos Healthcare Ltd filed Critical Ineos Healthcare Ltd
Publication of BRPI0606923A2 publication Critical patent/BRPI0606923A2/pt
Publication of BRPI0606923B1 publication Critical patent/BRPI0606923B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02Magnesium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Iron (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SUBSTáNCIA PARA USO COMO UM MEDICAMENTO, USO DE UMA SUBSTáNCIA, MéTODO DE MANUFATURA DE UMA SUBSTáNCIA PARA USO COMO UM MEDICAMENTO, FORMULAçãO FARMACêUTICA, E, MéTODO DE MANUFATURA DE UMA FORMULAçãO FARMACêUTICA. Uma substância para uso como um medicamento, compreende um composto de metal misturado sólido de fórmula (I): M^ II^~ 1-a~M^ III^~ a~O~ b~A^ n-^ ~ c~zH~ 2~O (1) onde M^ II^ é pelo menos um metal bivalente; M^ III^ é pelo me nos um metal trivalente; A^ n-^ é pelo menos um ânion n-valente; 2 + a = 2b + <sym>cn < 0,9a. A substância pode ser produzida pelo aquecimento em uma temperatura de 200°C a 600°C, preferivelmente de 250°C a 500°C de uma substância que compreende um composto de fórmula (II): M^ II^~ 1-X~M^ III^~ X~(OH)~ 2~A^ n-^~ y~mH~ 2~O (II) onde M^ II^ é pelo menos um metal bivalente; M^ III^ é pelo menos um metal trivalente; A~ n-~ é pelo menos um ânion n-valente; x = <sym>yn O <x <243> 0,5, O <y <243> 1 e 0 < m <243> 10.
BRPI0606923-1A 2005-02-10 2006-02-09 Substância para uso como um medicamento, uso de uma substância, método de manufatura de uma substância para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica BRPI0606923B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0502787.5A GB0502787D0 (en) 2005-02-10 2005-02-10 Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
GB0502787.5 2005-02-10
PCT/GB2006/000452 WO2006085079A2 (en) 2005-02-10 2006-02-09 Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use

Publications (2)

Publication Number Publication Date
BRPI0606923A2 true BRPI0606923A2 (pt) 2009-12-01
BRPI0606923B1 BRPI0606923B1 (pt) 2019-06-18

Family

ID=34356109

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606923-1A BRPI0606923B1 (pt) 2005-02-10 2006-02-09 Substância para uso como um medicamento, uso de uma substância, método de manufatura de uma substância para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica

Country Status (20)

Country Link
US (2) US20080206358A1 (pt)
EP (2) EP1850859B1 (pt)
JP (2) JP5328157B2 (pt)
KR (3) KR20070082918A (pt)
CN (2) CN105412150B (pt)
AR (2) AR053678A1 (pt)
AU (1) AU2006213922B2 (pt)
BR (1) BRPI0606923B1 (pt)
CA (1) CA2597124C (pt)
ES (1) ES2599152T3 (pt)
GB (1) GB0502787D0 (pt)
IL (1) IL184448A (pt)
MX (1) MX2007009688A (pt)
MY (1) MY150070A (pt)
NO (2) NO341846B1 (pt)
NZ (1) NZ556600A (pt)
RU (1) RU2420297C2 (pt)
TW (1) TWI461201B (pt)
WO (1) WO2006085079A2 (pt)
ZA (1) ZA200706160B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
GB201005931D0 (en) 2010-04-09 2010-05-26 Isis Innovation Immune modulation
US9649335B1 (en) * 2016-03-30 2017-05-16 Baylor University Intravenous administration of an oxygen-enabled fluid
AU2019363816A1 (en) 2018-10-25 2021-05-13 Eirgen Pharma Ltd. Methods of treatment with mixed metal compounds
RU2758671C1 (ru) * 2020-12-08 2021-11-01 Федеральное государственное бюджетное учреждение науки Институт физики прочности и материаловедения Сибирского отделения Российской академии наук (ИФПМ СО РАН) СПОСОБ ПОЛУЧЕНИЯ НАНОСТРУКТУРНЫХ ДВОЙНЫХ ГИДРОКСИДОВ НА ОСНОВЕ АЛЮМИНИЯ И ЩЕЛОЧНОЗЕМЕЛЬНЫХ МЕТАЛЛОВ, ТАКИХ КАК МАГНИЙ ИЛИ КАЛЬЦИЙ, ОБЛАДАЮЩИХ СВОЙСТВОМ ПОВЫШАТЬ pH КЛЕТОЧНОЙ СРЕДЫ, И НАНОСТРУКТУРЫ, ПОЛУЧЕННЫЕ ДАННЫМ СПОСОБОМ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2838930C2 (de) * 1978-09-07 1980-07-03 Chemische Werke Huels Ag, 4370 Marl Wäßriges Behandlungsmittel für Holz und Holzwerkstoffe und dessen Verwendung
US4514389A (en) * 1981-05-06 1985-04-30 Kyowa Chemical Industry Co. Ltd. Gastric antacid and method for controlling pH of gastric juice
JPS606619A (ja) * 1983-06-27 1985-01-14 Kyowa Chem Ind Co Ltd 鉄分欠乏症処置剤及びその製法
US4566986A (en) * 1984-08-31 1986-01-28 Waldmann John J Flocculating agents and processes for making them
US5153156A (en) * 1989-04-18 1992-10-06 Aristech Chemical Corporation Process for making efficient anionic clay catalyst, catalysts made thereby, and method of making isophorone
US5246899A (en) * 1991-08-16 1993-09-21 Amoco Corporation Simplified preparation of hydrotalcite-type clays
NL9201907A (nl) * 1992-11-02 1994-06-01 Tno Peristaltisch mengende reactor en peristaltische kleppenpomp.
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
WO2003003809A2 (en) * 2001-07-05 2003-01-16 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
JP4348426B2 (ja) * 2002-08-29 2009-10-21 独立行政法人産業技術総合研究所 高選択性脱リン剤及びその製造方法
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EP1696889A1 (en) * 2003-08-28 2006-09-06 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of benzimidazole and processes for their preparation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate

Also Published As

Publication number Publication date
NO20171769A1 (no) 2007-11-12
JP2008530065A (ja) 2008-08-07
TWI461201B (zh) 2014-11-21
KR20130121186A (ko) 2013-11-05
GB0502787D0 (en) 2005-03-16
IL184448A (en) 2014-12-31
NO20074504L (no) 2007-11-12
KR20070082918A (ko) 2007-08-22
ZA200706160B (en) 2009-02-25
AR053678A1 (es) 2007-05-16
KR20140066756A (ko) 2014-06-02
AU2006213922B2 (en) 2011-09-29
CN105412150B (zh) 2019-05-17
AU2006213922A2 (en) 2006-08-17
WO2006085079A2 (en) 2006-08-17
NZ556600A (en) 2010-02-26
MX2007009688A (es) 2008-01-22
EP1850859B1 (en) 2016-07-20
CA2597124C (en) 2015-11-24
CN101115490A (zh) 2008-01-30
US20120093943A1 (en) 2012-04-19
KR101491531B1 (ko) 2015-03-09
AR106699A2 (es) 2018-02-07
JP5328157B2 (ja) 2013-10-30
WO2006085079A3 (en) 2006-12-14
JP2013209401A (ja) 2013-10-10
MY150070A (en) 2013-11-29
ES2599152T3 (es) 2017-01-31
BRPI0606923B1 (pt) 2019-06-18
RU2007133720A (ru) 2009-03-20
CA2597124A1 (en) 2006-08-17
NO341846B1 (no) 2018-02-05
EP1850859A2 (en) 2007-11-07
IL184448A0 (en) 2007-10-31
US20080206358A1 (en) 2008-08-28
AU2006213922A1 (en) 2006-08-17
RU2420297C2 (ru) 2011-06-10
CN105412150A (zh) 2016-03-23
TW200640476A (en) 2006-12-01
CN101115490B (zh) 2015-12-09
EP3120855A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
BRPI0606923A2 (pt) substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
UY30472A1 (es) Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones.
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
TW200615266A (en) Organic compounds
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
NO20092033L (no) Nye forbindelser
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
UY28702A1 (es) Derivados de quinazolina
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
CO5560555A2 (es) Cristales de derivado de hidroxinorefedrina
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
ECSP099080A (es) Combinaciones farmacológicas para el tratamiento de enfermedades de las vías aéreas
DOP2005000250A (es) Amidas de acido pirazindicarboxilico y su uso
SE0101978D0 (sv) New compounds
UY30705A1 (es) Sulfonamidas sustituidas

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B25A Requested transfer of rights approved

Owner name: CYTOCHROMA DEVELOPMENT INC. (BB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2617 DE 02-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.